Abstract
The alveolar region of the mammalian lung seems to offer a promising route for the systemic delivery of certain protein and peptide biopharmaceuticals which otherwise must be injected (Bensch et al., 1967; Byron, 1990; Dominquez et al., 1967; Patton and Platz, 1992). The absorption of these molecules into the systemic circulation is thought to occur by diffusion in the conducting airways (Taylor and Gaar, 1970) and by diffusion and transcytosis in the alveolar region of the lungs (Patton and Platz, 1992). Diffusion of lipid-soluble drugs approximately parallels the lipid/water partition coefficients of the compounds as measured at pH 7.4, which suggests that diffusion is occurring through lipid structures. Drugs with very low lipid solubilities are absorbed at rates inversely related to the size of the molecule. This absorption is driven by a concentration gradient, suggesting the presence of “aqueous pores.” The morphological correlate of aqueous pores is uncertain but may be tight junctions. Molecules greater than 2.3 nm in diameter, corresponding to molecular weights of 10 kDa, cannot diffuse through the tight junctions of the intestinal epithelial cells which are roughly similar to those in the airways (Madara, 1989; Taylor and Gaar, 1970). Transcytosis is a process where cells of the alveolar lining form endocytic sacs that carry fluid and solutes from the alveolar lumen into the interstitium. It is hypothesized that depending on the molecular size, molecules in the interstitium may transcytose through and/or diffuse between the capillary endothelial cells into the bloodstream. If the molecule is greater than 25–50 kDa in size, its transport across the capillary endothelium may be blocked by the basement membrane, and instead it will diffuse into the lymphatic system and eventually ends up in the circulation (Hubbard et al., 1989; Taylor and Gaar, 1970).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bensch, K. G., Dominquez, E. A. M., and Liebow, A. A., 1967, Absorption of intact protein molecules across the pulmonary air—tissue barrier, Science 157:1204–1206.
Brain, J. D., and Valberg, P. A., 1979, Deposition of aerosol in the respiratory tract, Am. Rev. Respir. Dis. 120:1325–1373.
Brain, J. D., Knudson, D. E., Sorokin, S. P., and Davis, M. A., 1976, Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation, Environ. Res. 11:13–33.
Brown, R. A., Jr., and Schanker, L. S., 1983, Absorption of aerosolized drugs from the rat lung, Drug Metab. Dispos. 11:355–360.
Byron, P., 1990, Determinants of drug and polypeptide bioavailability from aerosols delivered to the lung, Adv. Drug Deliv. Rev. 5:107–132.
Byron, P. R., and Niven, R. W., 1988, A novel dosing method for drug administration to the airway of the isolated rat lung, J. Pharm. Sci. 77:693–695.
Byron, P. R., Roberts, N. S. R., and Clark A. R., 1986, An isolated perfused rat lung preparation for the study of aerosolized drug deposition and absorption, J. Pharm. Sci. 75:168–171.
Colthorpe, P., Farr, S. J., Taylor, G., Smith, I. J., and Wyatt, D., 1991, The pharmacokinetics of pulmonary-delivered insulin: A comparison of intratracheal and aerosol administration to the rabbit, Pharm. Research 9:764–768.
Dolovich, M., 1989, Physical principles underlying aerosol therapy. J. Aerosol Med. 2(2):171–186.
Dominquez, E. A. M., Liebow, A. A., and Bensch, K. G., 1967, Studies on the pulmonary air—tissue barrier. I. Absorption of albumin by the alveolar wall, Lab. Invest. 16:905–911.
Eljamal, M., Wong, L. B., and Yeates, D. B., 1994, Capsaicin-activated bronchial and alveolar-initiated pathways regulating tracheal ciliary beat frequency, J. Appl. Physiol. 77(3):1239–1245.
Enna, S. J., and Schanker, L. S., 1972, Absorption of saccharides and urea from rat lung, Am. J. Physiol. 222:409–414.
Fisher, A. B., Dodia, C., and Linask, J., 1980, Perfusate composition and edema formation in isolated rat lungs, Exp. Lung Res. 1:13–21.
Hubbard, R. C., Casolaro, M. A., Mitchell, M., Sellers, S. E., Arabia, F., Matthay, M. A., and Crystal, R. G., 1989, Fate of aerosolized recombinant DNA-producing al-antitrypsin: Use of the epithelial surface of the lower respiratory tract to administer proteins of therapeutic importance, Proc. Natl. Acad. Sci. USA 86:680–684.
Ilowite, J. S., Baskin, M. I., Sheetz, M. S., and Abd, A. G., 1991, Delivered dose and regional distribution of aerosolized pentamidine using different delivery systems, Chest 99:1139–1144.
Levey, S., and Gast, R., 1966, Isolated perfused rat lung preparation, J. Appl. Physiol. 21:313–316.
Madara, J. L., 1989, Loosening tight junctions: Lessons from the intestine, J. Clin. Invest. 83:1089–1094.
Niemeier, R. W., 1984, The isolated perfused lung, Environ. Health Perspect. 56:35–41.
Niemeier, R. W., and Bingham, E., 1972, An isolated perfused lung preparation for metabolic studies, Life Sci. 11:807–820.
Niven, R. W., and Byron, P. R., 1987, Solute absorption from the airways of the isolated rat lung. I. The use of absorption data to quantify drug dissolution or release in the respiratory tract, Pharm. Research 5:574–579.
Niven, R. W., Whitcomb, L., Wilson, J. V., Kinstler, O., and Shaner, L., 1994, Intratracheal instillation vs aerosol administration of rhG-CSF and PEGylated rhG-CSF, Pharm. Res. 11:S289.
Patton, J. S., and Platz, R. M., 1992, Pulmonary delivery of peptide and proteins for systemic action, Adv. Drug Deliv. Rev. 8:179–196.
Pritchard, J. N., Holmes, A., Evans, N., Evans, R. J., and Morgan, A., 1985, The distribution of dust in the rat lung following administration by inhalation and by single intratracheal instillation, Environ. Res. 36:268–297.
Smaldone, G. C., Fuhrer, J., Steigbigel, R. T., and McPeck, M., 1991, Factors determining pulmonary deposition of aerosolized pentamidine in patients with human immunodeficiency virus infection, Ann. Rev. Respir. Dis. 143:727–737.
Smith, R. M., Traber, L. D., Traber, D. L., and Spragg, R. G., 1989, Pulmonary deposition and clearance of aerosolized alpha-1-proteinase inhibitor administered to dogs and sheep, J. Clin. Invest. 84:1145–1154.
Stahlhofen, W., Gebhart, J., and Heyder, J., 1980, Experimental determination of the regional deposition of aerosol particles in the human respiratory tract, Am. Ind. Hyg. Assoc. J. 41:385–398.
Taylor, A. E., and Gaar, K. A., Jr., 1970, Estimation of equivalent pore radii of pulmonary and alveolar membranes, Am. J. Physiol. 218:1133–1140.
Taylor, G., Colthorpe, P., and Farr, S. J., 1994, Human growth hormone pharmacokinetics in rabbits after selective regional pulmonary delivery, Pharm. Res. 11:S289.
Timbrell, V., Hyett A. W., and Skidmore, J. W., 1968, A simple dispenser for generating dust clouds from standard reference samples of asbestos, Ann. Occup. Hyg. 11:273–281.
Wright, B. M., 1950, A new dust-feed mechanism, J Sci. Inst. 27:12–15.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer Science+Business Media New York
About this chapter
Cite this chapter
Eljamal, M., Nagarajan, S., Patton, J.S. (1996). In Situ and in Vivo Methods for Pulmonary Delivery. In: Borchardt, R.T., Smith, P.L., Wilson, G. (eds) Models for Assessing Drug Absorption and Metabolism. Pharmaceutical Biotechnology, vol 8. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-1863-5_19
Download citation
DOI: https://doi.org/10.1007/978-1-4899-1863-5_19
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-1865-9
Online ISBN: 978-1-4899-1863-5
eBook Packages: Springer Book Archive